PISA. The effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute stroke: Protocol for a phase II double-blind randomised placebo-controlled trial [ISRCTN98608690] by Breda, Eric J van et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Cardiovascular Disorders
BMC Cardiovascular Disorders  2002,  2 x Study protocol
PISA. The effect of paracetamol (acetaminophen) and ibuprofen on 
body temperature in acute stroke: Protocol for a phase II 
double-blind randomised placebo-controlled trial 
[ISRCTN98608690]
Eric J van Breda†1, Bart van der Worp†2, Maarten van Gemert†3, 
Ron Meijer†1, Jaap Kappelle†2, Peter J Koudstaal†1 and 
Diederik W Dippel†*1 for the PISA-investigators
Address: 1Department of Neurology, University Hospital Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands, 2Department of 
Neurology, University Medical Centre Utrecht, PO Box 85500 3508 GA Utrecht, The Netherlands and 3Department of Neurology, Ziekenhuis 
Eemland, Ringweg Randenburg 110, 3816 CP Amersfoort, The Netherlands
E-mail: Eric Breda - breda@neuro.fgg.eur.nl; Bart van der Worp - H.B.vandeWorp@neuro.azu.nl; Maarten Gemert - vgemert@worldonline.nl; 
Ron Meijer - meijer@neur.azr.nl; Jaap Kappelle - l.kappelle@neuro.azu.nl; Peter J Koudstaal - koudstaal@neur.azr.nl; 
Diederik W Dippel* - dippel@neuro.fgg.eur.nl; the PISA-investigators - dippel@neuro.fgg.eur.nl
*Corresponding author      †Equal contributors
Abstract
Background: During the first days after stroke, one to two fifths of the patients develop fever or
subfebrile temperatures. Body temperature is a strong prognostic factor after stroke.
Pharmacological reduction of temperature in patients with acute ischaemic stroke may improve
their functional outcome. Previously, we studied the effect of high dose (6 g daily) and low dose (3
g daily) paracetamol (acetaminophen) in a randomised placebo-controlled trial of 75 patients with
acute ischemic stroke. In the high-dose paracetamol group, mean body temperature at 12 and 24
hours after start of treatment was 0.4°C lower than in the placebo group. The effect of ibuprofen,
another potent antipyretic drug, on body-core temperature in normothermic patients has not been
studied.
Aim: The aim of the present trial is to study the effects of high-dose paracetamol and ibuprofen
on body temperature in patients with acute ischaemic stroke, and to study the safety of these
treatments.
Design: Seventy-five (3 ×  25) patients with acute ischaemic stroke confined to the anterior
circulation will be randomised to treatment with either: 400 mg ibuprofen, 1000 mg
acetaminophen, or with placebo 6 times daily during 5 days. Body-temperatures will be measured
with a rectal electronic thermometer at the start of treatment and after 24 hours. An infrared
tympanic thermometer will be used to monitor body temperature at 2-hour intervals during the
first 24 hours and at 12-hour intervals thereafter. The primary outcome measure will be rectal
temperature at 24 hours after the start of treatment. The study results will be analysed on an
intent-to-treat basis, but an on-treatment analysis will also be performed. No formal interim
analysis will be carried out.
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Background
During the first days after stroke, between one and two
fifths of the patients develop fever or subfebrile tempera-
tures. [1–4] Increased temperatures have been associated
with relatively large infarct volumes, high case fatality,
and poor functional outcome, even after adjustment for
initial stroke severity. [2–6] The period in which hyper-
thermia is associated with poor outcome is probably lim-
ited to the first 12 or 24 hours from stroke onset. [6,7]
The harmful effects of an early rise in body temperature
have been attributed to increased cerebral metabolic de-
mands, [8] changes in the blood-brain barrier permeabil-
ity, acidosis, and an increased release of excitatory amino
acids. [9] In animal models of temporary focal cerebral
ischemia, mild intra-ischaemic hyperthermia increased
infarct volume, [10] whereas mild hypothermia reduced
infarct size. [11]
The above suggests that a pharmacological reduction of
temperature in patients with acute ischaemic stroke may
improve their functional outcome. Previously, we studied
the effect on body temperature of high (6 g daily) and me-
dium dose (3 g daily) paracetamol (acetaminophen) in a
randomised placebo controlled trial of 3 ×  25 patients
(PAPAS: paracetamol (acetaminophen) in patients with
acute stroke). [12] In the high dose paracetamol group,
mean body temperature at 12 and 24 hours after start of
treatment was 0.4°C (95% CI:0 – 0.8°) lower than in the
placebo group. Koennecke conducted a comparable study
of 40 patients with acute stroke. He showed that treatment
with paracetamol in a daily dose of 4000 mg resulted in a
substantial reduction of the proportion of patients with
body temperatures over 37.5°C, but he did not estimate
the size of the temperature reduction. [13]
Kasner et al. conducted a partly blinded trial of paraceta-
mol against placebo in 39 patients with haemorrhagic or
ischemic stroke, and oberved a difference of 0.2°C in body
temperature. The patients who received paracetamol tend-
ed to be more often hypothermic (<36.5°C) and less often
hyperthermic (>37.5°C), but these results were not statis-
tically significant. [14] In this study, a lower dose (3.9 g
daily) was used than in our study (6 g daily).
Several studies in adults and children with fever suggest a
larger antipyretic effect from ibuprofen than from para-
cetamol. [15–17] The effect of ibuprofen on body-core
temperature in normothermic and subfebrile patients
with stroke, who may have a disturbance of thermoregu-
lation,[18] has not been studied.
Pharmacological properties and toxicity of ibuprofen
Ibuprofen is a prostaglandin-synthetase inhibitor with an-
algesic, anti-inflammatory, and antipyretic features. It be-
longs to the group of propionic acid derivatives. It is
usually well tolerated, has almost no side effects or drug
interactions at therapeutic doses, and it affects the platelet
aggregation in doses of more than 1 g by reversible inhi-
bition of cyclo-oxygenase.
After oral administration, ibuprofen is rapidly absorbed;
the maximum concentration is reached after 1 to 2 hours.
Rectal administration leads to a slightly slower absorp-
tion. Ibuprofen is bound for 90% to 99% to plasma pro-
teins, but at usual concentrations only a small part of the
binding sites is occupied.
Ibuprofen is mainly distributed in the plasma compart-
ment; the distribution volume is approximately 0.15 I/kg
body weight. Elimination through the urine is almost
complete within 24 hours. The metabolites do not have
any detectable activity. More than 90% of a dose is found
back as metabolites and their conjugates in the urine. Less
than 1% is excreted as unchanged ibuprofen. The plasma
half-life is 1.5 to 2.5 hours. Gastrointestinal side effects,
including epigastric pain, nausea, heartburn, and sensa-
tions of fullness, are experienced by 5 to 15% of patients
taking ibuprofen. The frequency of these side effects is
lower than that of indomethacin or aspirin. A meta-anal-
ysis even showed that there is no significant difference in
adverse effects in patients treated with ibuprofen in daily
doses up to 1200 mg compared with patients given place-
bo. [19] Estimates of the incidence of gastro-intestinal
haemorrhage in patients with acute stroke range from
0.1% to 3%. [20,21] Whether treatment with non-steroi-
dal anti-inflammatory drugs (NSAID) increases the risk of
this complication in these patients is likely, but unknown.
Other side effects have been reported incidentally. These
include toxic amblyopia, fluid retention, edema, skin
rashes, and thrombocytopenia. Several cases of aseptic
meningitis, probably caused by ibuprofen, have been re-
ported. Allopecia has been described in negroid women
who also used relaxing hair lotions and steroids simulta-
neously. Teratogenic effects have not been reported. [22]
Pharmacological properties and toxicity of paracetamol
Paracetamol (N-acetyl-p-aminophenol) is a para-ami-
nophenol derivative and the major metabolite of phen-
acetin. It has a weak inhibitory effect on peripheral
biosynthesis (which accounts for its weak anti-inflamma-
tory activity), but it is a potent inhibitor of prostaglandin
production within the central nervous system. This pre-
sumably accounts for its analgesic and antipyretic proper-BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/7
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ties. It is rapidly absorbed through the gastrointestinal
tract and uniformly distributed through most body fluids.
After oral administration peak plasma levels are reached
after 30 min to 1 hour. [23] Rectal administration leads to
a slightly slower absorption, but effective plasma levels
are reached after approximately one hour. [24,25] Aceta-
minophen is mainly conjugated in the liver, and then ex-
creted in the urine. Plasma half-life is 1.5 to 3 hours.
Following a dose of 140 mg/kg bodyweight or more, the
glucuronide pathway may become saturated, and (hepa-
to-) toxicity may result. In patients with chronic liver fail-
ure, the threshold for toxicity is lower. [23] These patients
will therefore be excluded from the present study.
Methods and design
This study is a three-armed, randomised, double-blind,
placebo-controlled trial, performed in the university hos-
pitals of Rotterdam and Utrecht, and in the regional hos-
pital "Eemland" in Amersfoort, The Netherlands.
Aim of the study
To study the effect of high-dose ibuprofen and to confirm
the previously observed reducing effect of high-dose para-
cetamol on body temperature, and to study their safety in
normothermic and subfebrile patients with acute ischae-
mic stroke.
Study medication
Patients will be treated for 5 days with paracetamol or ibu-
profen in daily doses of 6 ×  1000 mg or 6 ×  400 mg, re-
spectively, or with placebo. The study drug will be
administered through identical capsules. The first gift of
medication may be given as a suppository. The study med-
ication will be provided in white paper boxes, numbered
consecutively with a medication number. Each box con-
tains 70 identical capsules containing paracetamol 500
mg, ibuprofen 200 mg, or placebo, and one suppository,
containing paracetamol 1000 mg, ibuprofen 400 mg, or
placebo. Every gift of medication consists of 2 capsules ex-
cept the first gift, which is one suppository. The study-
population will be stratified according to the time since
onset of stroke (0 to 12 hours vs 12 to 24 hours).
Randomisation and treatment schedule
Treatment allocation will be random. The randomisation
will be blocked in lots of six. A computer-generated list
containing the medication number and information on
the nature of the treatment (placebo, paracetamol, or ibu-
profen) will reside with the independent safety committee
and with the study pharmacist. Treatment allocation of
any patient who is in the study will be disclosed before ter-
mination of the study if the safety committee deems this
necessary. Local clinical investigators may apply for dis-
closure of the treatment allocation of an individual pa-
tient by the study pharmacist. This will be reported to the
safety committee and to the steering committee by the
study pharmacist.
Pain should not be treated with NSAID. We advise co-
deine, 4 to 6 times 10 mg daily, or tramadol, 4 times 25 to
50 mg daily. When the treating physician judges that fever
should be treated in a patient, the study medication
should be stopped. The clinical investigators are advised
to prescribe low-dose aspirin in all patients.
Outcomes
The primary outcome will be body temperature at 24
hours from start of treatment. Secondary outcomes will be
change in baseline temperature at 1 and 5 days from start
of treatment, and time with elevated body temperature
(>37.0°C) (area under the curve) during the first 24 hours
and the first five days. The tertiary outcome is functional
outcome at 1 month, as determined by the scores on the
modified Rankin Scale (mRS) and Barthel Index (BI).
Setting
Ziekenhuis Eemland Amersfoort is a 600 bed regional
hospital. Annually, 150 patients with acute stroke are ad-
mitted. The University Medical Centre Utrecht has 1043
beds, and admits a similar number of patients with acute
ischaemic stroke. The University Hospital Rotterdam has
1229 beds. Annually, 250 patients with acute stroke are
admitted. All three hospitals have an acute stroke unit and
a dedicated stroke team.
Study organization
The study personnel consists of an executive committee
(RJM, EJB, DWJD, HMAvG, HBvdW), an advisory com-
mittee (PJK, UK), and an independent data-monitoring
and safety committee.
The co-ordinating centre for data management is located
in Rotterdam. The investigators are responsible for patient
selection and inclusion, and data acquisition. The investi-
gators will notify the data management centre of newly in-
cluded patients and of serious adverse events within 72
hours.
The data-management centre is responsible for prompt
data entry. Every week, a progress report entailing all seri-
ous adverse events (infection, gastro-intestinal haemor-
rhage, liver function disturbance, neurological
deterioration, death, or other) will be provided by the ex-
ecutive committee. These data will be combined with the
randomisation scheme by the secretary of the data-moni-
toring and safety committee, and summarised in a simple
table. This table is forwarded to the other members of the
data-monitoring and safety committee. The members will
acknowledge receipt of the summary table. Upon receipt
of the safety data, each member of the safety committeeBMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/7
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will notify the advisory committee of his approval of con-
tinuation of the study. If one or more members of the safe-
ty committee express a concern with regard to the safety of
the study treatment, the chairman of the safety committee
will summon the members of the safety committee and
try to reach a consensus or majority advise. In light of the
small number of patients in the study, no formal statisti-
cal stopping rule is given.
Time path
In the previous study carried out in the same centres with
similar inclusion criteria, it took 8 months to include 75
patients, i.e. 2 patients per week. It is therefore not unre-
alistic to take eight months for patient inclusion, one
month to complete the follow-up and to close the data-
base, and one month to report the study. The study has
started in December 2000, and is expected to be complet-
ed at the end of the year 2001.
Inclusion criteria
Patients will be included if they have an acute ischaemic
anterior circulation stroke, a body temperature >36.0°C or
<39.0°C, a CT scan that is compatible with acute ischae-
mic stroke, a focal deficit without rapid improvement,
and a possibility to start treatment within 24 h after stroke
onset.
Exclusion criteria
Criteria for exclusion from this study are: 1) severe apha-
sia, defined as an aphasia score of 2 or 3 on the National
Institutes of Health Stroke Scale (NIHSS); 2) treatment
with an NSAID deemed necessary; 3) hypersensitivity to
ibuprofen or paracetamol, (chronic) liver failure or cir-
rhosis; 4) (chronic) renal failure; 5) history of alcohol
abuse; 6) active gastric ulcer disease or a history of peptic
ulceration or gastro-intestinal hemorrhage in the preced-
ing year; 7) colitis ulcerosa; 8) pregnancy; 9) use of corti-
costeroids; 10) a severe concomitant medical condition
that could affect the assessment of the effect of the study
medication on temperature; 11) residual neurological im-
pairment resulting from a previous stroke that may ham-
per the assessment of functional outcome; 12) death
appearing imminent, and 13) no informed consent given.
Study activities
In the first 24 hours, tympanic temperature will be meas-
ured in both ears every 2 hours. During the remaining 6
days, temperature will be measured twice a day. On the
first day, rectal temperature will be measured at start of
treatment (t = 0) and at t = 24 hours.
Day 0 is defined as the time period between onset of
stroke and inclusion in the study. All baseline investiga-
tions are therefore carried out on day 0. Day 1 commences
directly after the start of treatment with the study medica-
tion. All time-periods in the study are measured relative to
the time of start of treatment.
At baseline, the medical history, including previous
strokes or transient ischaemic attacks, will be assessed and
a general and neurological examination will be carried
out. The NIHSS is used to assess stroke severity at onset.
The mRS is used to determine the patients' pre-stroke
functional status. Laboratory investigations will include a
full blood count, glucose, electrolytes, creatinin, AST, ALT,
AF, LDH, γ GT, total bilirubin, APTT and PTT, and CRP. A
brain CT will be done before inclusion in the study.
Body-temperature will be measured with a tympanic ther-
mometer[26,27] at 2-hourly intervals during the first 24
hrs after start of treatment, and thereafter every 12 hours
until day 7. Temperatures will be taken from both ears,
and averaged. The baseline temperature (at the start of
treatment) and temperature at 24 hours after start of treat-
ment will be determined by both rectal and tympanic
thermometry. Compliance will be measured by counting
leftover pills, and by a registry of the medication that was
actually taken. Safety laboratory assessments will be car-
ried out on day 6, including hemoglobin, AST, ALT, AF,
LDH, γ GT, total bilirubin and CRP.
At the follow-up visit on day 28, mRS is used to assess
functional outcome. [28] The score on the BI will also be
assessed. Based on the neurological examination and the
results of CT, duplex, and other studies, etiological stroke
type will be determined according to the (modified) Trial
of Orgaran in Acute Stroke (TOAST) classification. [29]
Safety concerns and adverse events
One should be careful not to overlook infections in pa-
tients who are treated according to the study protocol.
Therefore, treating physicians are advised to lower their
thresholds for clinical suspicion of infection to 38°C, to
monitor the heart rate carefully, and start diagnostic stud-
ies and antibiotic treatment earlier than usual. The deci-
sion to start antipyretic mediciation in feverish patients is
left to the discretion of the treating physician. On such an
occasion, the study medication should be stopped.
Serious adverse events are defined as any deterioration in
health status that is potentially life threatening, and death,
within the study-monitoring period (day 0 to day 7). This
includes any life-threatening infection, such as pneumo-
nia, sepsis, or urinary tract infection that needs antibiotic
treatment according to the judgement of the treating phy-
sician, any liver function disturbance (AST, ALT, AF, or to-
tal bilirubin levels exceeding twice the local upper limit of
normal), gastro-intestinal haemorrhage, and neurological
deterioration (i.e. decrease in consciousness level of more
than one point on the Glasgow coma scale, or a decreaseBMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/7
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of two or more points on the NIHSS). All serious adverse
events have to be reported within 72 hours to the inde-
pendent data-monitoring and safety committee.
Ethical considerations
Each patient will be given written information about the
study. Informed consent will be obtained verbally and in
writing before inclusion. If the patient is unable to write,
written consent will be obtained from an appropriate
source (spouse, child, or parent). The medical ethics com-
mittees of the three hospitals have approved this protocol.
Analysis
The study results will be analysed on intent-to-treat basis,
but an "on-treatment" analysis of primary and secondary
endpoints will be carried out. There will be no formal in-
terim analysis. The main results of the study will be pre-
sented as the mean difference in temperature between
each treatment group and the placebo group. The preci-
sion of these estimates will be expressed with 95% confi-
dence intervals, based on the t distribution. No
adjustments for multiple comparisons will be made. Mul-
tiple linear regression will be used to adjust for possible
confounding factors, such as age, stroke type, and stroke
severity. The main analysis will be carried out according to
the intent to treat principle, but an on treatment analysis
will be provided. The analysis will be carried out with the
STATA 7.0 statistical package. [30]
Sample size
Seventy-five (3 ×  25) patients will be included in the
study. In a recent cohort study of 162 patients admitted
within 48 hours from onset, conducted at the University
Hospital Rotterdam, mean rectal temperature was 36.6°C,
with a standard deviation of 0.6°C. In order to detect a dif-
ference in core body temperature at 24 hours from onset
of 0.5°C, with a significance level of α  = 0.05, and power
1–β  = 0.80, we need at least 23 patients in each treatment
group; this is rounded to 25. The primary outcome occurs
24 hours after start of treatment. We expect more than
90% compliance in this period. We therefore need only 2
extra patients per treatment for lost patients in the on-
treatment analysis.
Publication of study results
All publications will be authored by the members of the
executive committee and the advisory committee. Co-au-
thors are supposed to have contributed to the design, the
analysis and actual reporting of the study; their centres are
expected to include patients roughly proportional to the
number of acute stroke patients that are admitted annual-
ly.
Discussion
We report the protocol of a phase II trial that aims to as-
sess the feasibility of early temperature reduction in nor-
mothermic or subfebrile patients with acute stroke. This
study intends to confirm the previously observed temper-
ature-reducing effect of paracetamol (6 g daily) and to as-
sess the effect of ibuprofen 2.4 g daily.
The study is powered to find a difference of 0.5°C between
active treatment and placebo. Half a degree Celsius does
not seem much by itself, but body temperature has been
shown to be a very strong prognostic factor in patients
with acute stroke. For every degree Celsius of body tem-
perature the risk of poor outcome increases by 2.2. The
earlier the increase in temperature occurs, the stronger the
relationship between brain damage and high temperature
seems to be. [6,7]
Because of the consistently observed relation between
hyperthermia and poor outcome after stroke, it is com-
monly advised to treat all stroke patients with a raised
temperature with antipyretic drugs. [31,32] However, a
causal relationship between hyperthermia and poor out-
come has never been demonstrated, and subfebrile tem-
peratures and fever may just be epiphenomena of severe
brain damage. In addition, there is no evidence that a
pharmacological reduction of increased temperatures will
lead to an improved outcome. Preventive administration
of antipyretics may even mask infections and lead to de-
layed treatment with antibiotics. For these reasons, we
think that the efficacy of antipyretic drugs to improve out-
come after stroke has to be proven in a randomised con-
trolled trial before treatment with these agents is accepted
as a standard procedure. For the same reasons, we consid-
er it ethical to withhold antipyretics from stroke patients
with subfebrile temperatures in the placebo arm of such a
trial.
When the effect of paracetamol or ibuprofen on body
temperature in acute stroke has been established, a large,
pragmatic phase III study will be undertaken to assess the
effect of these cheap and well known drugs on functional
outcome after stroke.
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